Alex picture 2022_edited.jpg

Alex Blyth
Chief Executive Officer

Serial entrepreneur, inventor and conceptual biologist with 20 years’ experience in bringing over 50 novel biopharma therapies to market for companies like Pfizer, Allergan, abbVie, Amgen, Shire, Takeda, GSK & Sanofi. Alex founded LIfT after losing his mother to Pancreatic Cancer, and seeing a new way to beat cancer by giving patients the immunity of those who are innately resistant to cancer.

Martin picture.jpg

Martin Woodward
Principal Scientist

Martin brings over 20 years’ of academic and industrial science experience to his role as Principal Scientist at LIfT. As an experienced immunologist he has published high impact research and has been a founding scientist of biotech start-ups including GammaDelta Therapeutics. Martin is particularly focussed on the challenges in bringing cell therapies from the bench to the clinic, and holds a PhD from University College London. 

Panteli photo.jpg

Industry and medical expert with over 25 years of highly successful translational research, clinical, commercial, and international management experience across healthcare, with a focus in Haemato-Oncology. Trained Immunologist with extensive experience in haematopoietic stem cell transplantation and cell therapies. Led the development and launch of several major cancer drugs within Pharma, Biotech and CRO. Former CMO for Cell Therapeutics prior to successful sale.

Dr Panteli Theocharous
Chief Medical Officer

Rebecca Prue.jpeg

Dr Rebecca Prue
Head of Quality Control

An experienced cell and gene therapy quality assurance specialist with a unique blend of experience in both Quality Management and Production Management of Investigational Medicinal Products (IMPs), including over 15 years Quality Management of cell and gene therapy products. Also an Immunologist whose PhD subject was specifically on Neutrophils.

oxana pic.jpg

Over her 20 year career to date, Oxana has worked across multiply therapeutic modalities in both pharma and biotech settings, with significant experience discovering biologics for Oncology indications. Oxana specialises in successfully bringing cell therapies to clinic. Oxana was a founding scientist for cell therapy company GammaDelta Therapeutics before moving to lead discovery at Adaptate Biotherapeutics. Oxana holds a PhD from Moscow State University”.

Dr Oxana Polyakova
Chief Scientific Officer


Andrew Willis
Head of Regulatory

Regulatory advisor with 33 years of experience with regulatory affairs and pharmaceutical development.  Experience at multiple levels within pharmaceutical companies and most recently as Vice President for Regulatory Affairs, gaining significant experience in co-ordinating, planning and running global development projects relating to orphan products and ATMPs.